General MedicationsOPHTHALMICGeneric
ALAMAST
PEMIROLAST POTASSIUM
Standard Dose
0.1%
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary
Approval overview ALAMAST is listed in Drugs@FDA under application 021079 (NDA).
Review priority: PRIORITY Marketing status: Discontinued Active ingredient PEMIROLAST POTASSIUM Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.1% Sponsor SANTEN Submission history Latest submission status date: 2013-02-15 00:00:00.
Structured Monograph
Clinical summary
Approval overview ALAMAST is listed in Drugs@FDA under application 021079 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient PEMIROLAST POTASSIUM Form and strength SOLUTION/DROPS;OPHTHALMIC - 0.1% Sponsor SANTEN Submission history Latest submission status date: 2013-02-15 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.